Biohit Oyj Stock price

Equities

BIOBV

FI0009005482

Office Equipment

Market Closed - Nasdaq Helsinki 12:12:18 2024-03-28 pm EDT 5-day change 1st Jan Change
2 EUR +2.04% Intraday chart for Biohit Oyj +3.90% +6.10%
Sales 2024 * 15.3M 16.5M Sales 2025 * 17.4M 18.77M Capitalization 30.23M 32.6M
Net income 2024 * 1M 1.08M Net income 2025 * 2M 2.16M EV / Sales 2024 * 1.43 x
Net cash position 2024 * 8.4M 9.06M Net cash position 2025 * 10M 10.79M EV / Sales 2025 * 1.16 x
P/E ratio 2024 *
15.4 x
P/E ratio 2025 *
15.4 x
Employees 46
Yield 2024 *
-
Yield 2025 *
-
Free-Float 42.24%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.04%
1 week+3.36%
Current month+3.36%
1 month+3.63%
3 months+4.17%
Current year+6.10%
More quotes
1 week
1.89
Extreme 1.885
2.00
1 month
1.87
Extreme 1.865
2.00
Current year
1.80
Extreme 1.8
2.09
1 year
1.67
Extreme 1.665
2.22
3 years
1.05
Extreme 1.045
2.54
5 years
1.05
Extreme 1.045
4.30
10 years
1.05
Extreme 1.045
8.07
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 21-06-03
Director of Finance/CFO 34 20-12-31
Chief Tech/Sci/R&D Officer 53 21-12-31
Members of the board TitleAgeSince
Chairman 56 23-06-13
Founder 81 87-12-31
Director/Board Member 73 19-04-23
More insiders
Date Price Change Volume
24-03-28 2 +2.04% 17,606
24-03-27 1.96 +2.35% 16,881
24-03-26 1.915 +0.79% 5,193
24-03-25 1.9 -1.04% 29,428
24-03-22 1.92 -0.26% 5,610

Delayed Quote Nasdaq Helsinki, March 28, 2024 at 12:12 pm EDT

More quotes
Biohit Oyj is a Finland-based company engaged in the development, manufacture and marketing of diagnostic tests and analysis systems. The Company operates one business segment, named Diagnostics. The Diagnostics segment offers solutions for the early diagnosis and prevention of gastrointestinal diseases. It provides blood-sample examination based on GastroPanel for the diagnosis of stomach illnesses and associated risks, quick tests for the diagnosis of lactose intolerance and Helicobacter pylori infection in connection with gastroscopy, as well as the ColonView examination for the early detection of fecal occult intestinal bleeding, which indicates a risk of colorectal cancer. The Company's products are used in hospitals, healthcare centers and research institutions. It operates primarily in Europe and Asia. Furthermore, the Company is a parent of Biohit Healthcare Ltd, Biohit Healthcare Srl, Oy Finio Ab, and Vantaan Hienomekano Oy, among others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2 EUR
Average target price
2.4 EUR
Spread / Average Target
+20.00%
Consensus
  1. Stock
  2. Equities
  3. Stock Biohit Oyj - Nasdaq Helsinki